1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes

Diabetes Care

Volumn 29, Issue 6, 2006, Pages 1214-1219

  Dungan, Kathleen M ^a   Buse, John B ^a,e   Largay, Joseph ^a   Kelly, Mary M ^b   Button, Eric A ^c   Kato, Shuhei ^d   Wittlin, Steven ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c BioEmerge Partners Inc   (United States)

^d Tomen America   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; FRUCTOSAMINE; GLUCOSE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MONITORING, AMBULATORY; MONITORING, PHYSIOLOGIC; POSTPRANDIAL PERIOD; REPRODUCIBILITY OF RESULTS;

EID: 33746403773     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1910     Document Type: Article

References (27)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of the long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas of insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
4. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
5. Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P, Verlato G: Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 23:45-50, 2000
6. 1c level. Diabetes Care 23:1830-1834, 2000
7. Erlinger TP, Brancati FL: Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 24:1734-1738, 2001
8. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ: Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 8:1859-1865, 2004
9. Fukumura Y, Tajima S, Oshitani S, Ushijima Y, Kobayashi I, Hara F, Yamamoto S, Yabuuchi M: Fully enzymatic method for determining 1,5-anhydro-D-glucitol in serum. Clin Chem 40:2013-2016, 1994
10. Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, Miyashita H, Akaoka I: Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 263:E268-E273, 1992
11. Yamanouchi T, Akanuma H, Asano T, Konishi C, Akaoka I, Akanuma Y: Reduction and recovery of plasma 1,5-anhydro-D-glucitol level in diabetes mellitus. Diabetes 36:709-715, 1987
12. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, Akaoka I: Plasma 1,5-anhydro-d-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 38:723-729, 1989
13. Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I: Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1C and 1,5 anhydroglucitol. Metabolism 41:862-867, 1992
14. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H: Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 347:1514-1518, 1996
15. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamore R, Kamada T: 1,5-anhydro-d-glucitol evaluated daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18:1156-1159, 1995
16. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mastrototaro JJ: Performance evaluation of the MiniMed Continuous Glucose Monitoring System during patient home use. Diabetes Technol Ther 2:49-56, 2000
17. Chase HP, Kim LM, Owen SL, MacKenzie TH, Klingensmith GS, Murtfeldt R, Garg SK: Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 107:222-226, 2001
18. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P: A pilot study of glucose measurements using the glucose sensor. Diabetes Care 25:1185-1191, 2002
19. Sachedina N, Pickup JC: Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in type 1 diabetic subjects. Diabet Med 20:1012-1015, 2003
20. Tansey MJ, Beck RW, Buchingham BA, Mauras N, Fiallo-Scharer R, Xing D, Killman C, Tambourlane WV, Ruedy KJ, the Diabetes Research in Children Network (DirecNet) Study Group: Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes Technol Ther 7:109-114, 2005
21. Steiger JH: Tests for comparing elements of a correlation matrix. Psychol Bull 87:195-201, 1980
22. Kawasaki I, Sato T, Hosoi M, Yoshioka K, Yamakita T, Fukumoto M, Tanaka N, Natsuyama H, Ueda M, Fujii S: Serum 1,5-anhydroglucitol is a strong predictor of the postprandial hyperglycemia in type 2 diabetes patients (Abstract). Diabetes 54 (Suppl. 1):A76, 2005
23. Moses A, Raskin P, Hu P, Allen E: Serum 1,5-anhydroglucitol (GlycoMark) as a marker of glycemic control in subjects receiving twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) vs. once-daily insulin glargine in patients with type 2 DM on oral antidiabetic agents (Abstract). Diabetes 54 (Suppl. 1):A96, 2005
24. 1c in pediatric type 1 diabetic patients. Diabetes Care 25:1840-1844, 2002
25. 1c. Diabetes Care 26:881-885, 2003
26. Yamanouchi T, Akanuma Y: Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 24 (Suppl.):S261-S268, 1994
27. Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM: Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet Med 16:496-499, 1999